Skip to main content
Publications
Fasching PA, Hall PS, Chang L, Parikh R, Hitchens A, Davis KL, Sjekloca N, Summerhayes M, Ntalla I, Derrien Ansquer V, Bergamaco E, Ghabaireh M. Real-world clinical outcomes among patients (pts) with metastatic/advanced triple-negative breast cancer (mTNBC) in the United Kingdom (UK) and Germany (GER). Poster presented at the 2023 ESMO Breast Cancer Annual Congress; May 11, 2023. Berlin, Germany.
Oikonomidou O, Galve-Calvo E, Wockel A, Parikh R, Hitchens A, Chen C, Gauthier E, Li B, Derrien Ansquer V, Frugier G, Jimenez M, Davis KL, Broughton EI. Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2_ advanced breast cancer in Europe. Poster presented at the 2023 ESMO Breast Cancer Annual Congress; May 2023. Berlin, Germany.
Law EH, Galve-Calvo E, Wockel A, Parikh R, Kurosky SK, Derrien Ansquer V, Frugier G, Davis KL, Esterberg E, Oikonomidou O. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Poster presented at the 2021 San Antonio Breast Cancer Symposium (SABCS); December 7, 2021. San Antonio, TX. [abstract] Cancer Res. 2022 Feb 15; 82(4_Suppl):OT2-19-04. doi: 10.1158/1538-7445.SABCS21-OT2-19-04
Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871